More on SRPT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $18.18 |
|
|||
| Open | $17.94 | ||||
| 52 Wk High | $63.73 | ||||
| 52 Wk Low | $8.00 | ||||
| Day High | $18.12 | ||||
| Day Low | $17.16 | ||||
| P/E | N/A | ||||
| EPS | $-5.69 | ||||
| Volume | 1,285,459 | ||||
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
- Sarepta preclinical data shows SRP-1003 reduces DM1 RNA in nucleus
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
- Sarepta Therapeutics (SRPT) PT Lowered to $17 at RBC Capital
- H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorgan
- Sarepta's Elevidys shows benefit in older Duchenne patients
- Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde
Entities mentioned with SRPT
- FDA | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
